September news: MHRA licences will allow UK industry to manufacture innovative medicines

How will the newly MHRA licenced CGT Catapult manufacturing centre support developers in the UK?

In this newsletter:

  • How will the newly MHRA licenced CGT Catapult manufacturing centre support developers in the UK?
  • What are the implications of cost-utility analysis and budget impact methodologies? Listen to our heath economics webinar.
  • Find out about preclinical development of cell-based medicinal products for European markets

Your privacy

We use cookies on this site to enhance your user experience.
By clicking the Accept button, you agree to us doing so. Find out more here.